Design, Synthesis and Anticonvulsant Activity Evaluation of Novel 4-(4-Substitutedphenyl)-3-Methyl-1H-1,2,4-Triazol-5(4H)-Ones

Abstract

A series of novel 4-(4-substitutedphenyl)-3-methyl-1H-1,2,4-triazol-5(4H)-one derivatives were synthesized and screened for their anticonvulsant activities by the maximal electroshock test (MES) and their neurotoxicity was evaluated by the rotarod neurotoxicity test (TOX). In the MES test, compound 4-{4-[(3-fluorobenzyl)oxy]phenyl}-3-methyl-1H-1,2,4-triazol-5(4H)-one (4n) was found to possess better anticonvulsant activity and higher safety than marketed drugs Carbamazepine with an ED₅₀ value of 25.5 mg/kg and protective index (PI) value>48.8. In addition, the potency of compound 4n against seizures induced by Pentylenetetrazole, 3-Mercaptopropionic acid, and Bicuculline suggested its broad spectrum activity, and the mechanisms of action including inhibition of voltage-gated ion channels and modulation of GABAergic activity might involve in its anticonvulsant activity.

Key words

triazolone - anticonvulsant - mechanism - GABA

• References

• 1 Strine TW, Kobau R, Chapman DP et al. Psychological distress, comorbidities, and health behaviors among U.S. adults with seizures: results from the 2002 National Health Interview Survey. Epilepsia. 2005 46. 1133-1139
• 2 Mc Namara OJ, Brunton LL, Lazo JS, et al. eds. The Pharmacological Basis of Therapeutics. New York: McGraw-Hill; 2006: 501-526
• 3 Husain A, Rashid M, Akhter A et al. Design, synthesis and pharmacological activities of novel N-1-2-(substituted phenyl)-4-oxo-1,3-thiazolan-3-yl-2,2-diphenyl-acetamides. Int J Pharm Sci Rev Res 2010; 5: 102-106
• 4 Stefan H, Feuerstein T. Novel anticonvulsant drugs. Pharmacol Ther 2007; 113: 165-183
• 5 Donner EJ, Snead OC. New generation anticonvulsants for the treatment of epilepsy in children. NeuroRX 2006; 3: 170-180
• 6 Bootsma HP, Ricker L, Hekster YA et al. The impact of side effects on long-term retention in three new antiepileptic drugs. Seizure 2009; 18: 327-331
• 7 Kennedy GM, Lhatoo SD. CNS adverse events associated with antiepileptic drugs. CNS Drugs 2008; 22: 739-760
• 8 Penovich PE, James Willmore L. Use of a new antiepileptic drug or an old one as first drug for treatment of absence epilepsy. Epilepsia 2009; 50: 37-41
• 9 Bialer M, Johannessen SI, Kupferberg HJ et al. Progress report on new antiepileptic drugs: a summary of the Eighth Eilat Conference (EILAT VIII). Epilepsy Res 2007; 73: 1-52
• 10 Bialer M, Yagen B. Valproic acid: second generation. Neurotherapeutics 2007; 4: 130-137
• 11 Husain A, Rashid M, Akhter A et al. Synthesis of new 1,2,4-triazolo3,4-B[1,3,4]thiadiazole derivatives and their pharmacological evaluation. J Pharm Res 2011; 4: 888-890
• 12 Unverferth K, Engel J, Hofgen N et al. Synthesis, Anticonvulsant Activity, and Structure-Activity Relationships of Sodium Channel Blocking 3-Aminopyrroles. J Med Chem 1998; 41: 63-73
• 13 Kaushik D, Khan SA, Chawla G. Design and synthesis of 2-(substituted aryloxy)-5-(substituted benzylidene)-3-phenyl-2,5-dihydro-1H-[1,2,4] triazin-6-one as potential anticonvulsant agents. Eur J Med Chem 2010; 45: 3960-3969
• 14 Hassan MZ, Khan SA, Amir M. Design, synthesis and evaluation of N-(substituted benzothiazol-2-yl)amides as anticonvulsant and neuroprotective. Eur J Med Chem 2012; 58: 206-213
• 15 Kaushik D, Khan SA, Chawla G et al. N’-[(5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)-methylene] 2,4-substituted hydrazides: Synthesis and anticonvulsant activity. Eur J Med Chem. 2010 45. 3943-3949
• 16 Siddiqui N, Ahsan W. Triazole incorporated thiazoles as a new class of anticonvulsants: Design, synthesis and in vivo screening. Eur J Med Chem 2010; 45: 1536-1543
• 17 Siddiqui N, Alam MS, Stables JP. Synthesis and anticonvulsant properties of 1-(amino-N-arylmethanethio)-3-(1-substitutedbenzyl-2,3-dioxo­indolin-5-yl) urea derivatives. Eur J Med Chem 2011; 46: 2236-2242
• 18 Jin HG, Sun XY, Chai KY et al. Anticonvulsant and toxicity evaluation of some 7-alkoxy-4,5-dihydro-[1,2,4]triazolo[4,3-a]quinoline-1(2H)-ones. Bioorg Med Chem 2006; 14: 6868-6873
• 19 Krall RJ, Penry JK, White BG et al. Antiepileptic drug development: II Anticovulsant drug screening. Epilepsia. 1978. 19. 409-428
• 20 Poter RJ, Cereghino JJ, Gladding GD et al. Antiepileptic drug development program. Cleve Clin 1984; 51: 293-305
• 21 Arnoldi A, Bonsignori A, Melloni P et al. Synthesis and anticonvulsant and sedative-hypnotic activity of 4-(alkylimino)-2,3-dihydro-4H-1-ben-zopyrans and -benzothiopyrans. J Med Chem 1990; 33: 2865-2869
• 22 Löscher W, Schmidt D. A proposal based on experimental and clinical considerations. Epilepsy Res 1988; 2: 145-181
• 23 White HS. Preclinical development of antiepileptic drugs: past, present, and future directions. Epilepsia 2003; 44: 2-8
• 24 Levy RH, Mattson RH, Meldrum BS. eds. General principles: experimental selection, quantification, and evaluation of antiepileptic drugs. New York: Raven Press; 1995: 99-110
• 25 Waterbeemed HV. The Practice of Medicinal Chemistry. London: Academic Press; 1996. 367.
• 26 Okada R, Negishi N, Nagaya H. The role of the nigrotegmental GABAergic pathway in the propagation of pentylenetetrazol-induced seizures. Brain Res 1989; 480: 383-387
• 27 Olsen RW. GABA-benzodiazepine-barbiturate receptor interactions. J Neurochem 1981; 37: 1-13
• 28 Gale K. Basic concepts from preclinical research. Epilepsia 1992; 33: S3-S12
• 29 Löscher W. 3-Mercaptopropionic acid: Convulsant properties, effects on enzymes of the γ-aminobutyrate system in mouse brain and antagonism by certain anticonvulsant drugs, aminooxyacetic acid and gabaculine. Biochem Pharmacol 1979; 28: 1397-1407
• 30 Macdonald RL, Barker JL. Specific antagonism of GABA-mediated postsynaptic inhibition in cultured spinal cord neurons: a common mode of convulsant action. Neurology 1978; 28: 325-330